FDA
Ionis Filed Zilganersen for Sept. 22 FDA Decision; First AxD Drug
FDA accepted Ionis' filing for zilganersen for priority review last month, setting a September 22 deadline for what would be the first cleared treatment for…
Latest — Page 14
Deals
Buys Kashiv for $1.1B, Amneal Eyes $200B Biosimilar Market
Amneal paid $1.1 billion to buy Kashiv BioSciences: $750 million upfront in cash and equity at close, plus up to $350 million tied to pipeline milestones.
Deals
Forager Bids $1B for Repay at 75% Premium
Forager Capital Management offered $1 billion for Atlanta-based Repay Holdings at $4.80 a share, a 75% premium to the stock's 30-day volume-weighted average…
Legal
Smartmatic Fights First Corporate FCPA Indictment Since 2010
The U.S. government charged Smartmatic in October 2025 with conspiracy to violate the FCPA's anti-bribery provisions, money laundering conspiracy, and money…
FDA
Pancreatic Cancer Hits Herceptin-Style 1998 Turning Point
Since Herceptin's approval in 1998, breast cancer has moved from a near-term death sentence to, in many cases, a chronic disease.
FDA
Cut 2 Abelacimab Cancer Trials, Novartis Bets $925M on Afib
Novartis is now betting its entire $925 million abelacimab investment on one remaining trial after the factor XI/XIa inhibitor failed to beat Eliquis in…
Deals
Paid $1.25B, Apollo Takes 13% of McKesson's Surgical Unit
Apollo Funds paid $1.25B for a 13% minority stake in McKesson's Medical/Surgical Solutions division, valuing MMS at roughly $13 billion.
FDA
Kyverna Sweeps All KYSA-8 Endpoints: 46% SPS Improvement, FDA Filing Next
Kyverna Therapeutics posted the full KYSA-8 dataset for miv-cel in stiff person syndrome at the American Academy of Neurology annual meeting, showing a 46%…
FDA
Gilead Cuts Arcus TIGIT Option After Domvanalimab's 2 Trial Failures
Gilead Sciences is walking away from most of its TIGIT collaboration with Arcus Biosciences after STAR-121, a Phase 3 study of domvanalimab in metastatic…
AI
Utah Built the Clinical AI Sandbox Founders Are Racing Toward
If you're building clinical AI and haven't looked at Utah, you're late.
Legal
ESMA Orders Unlicensed Crypto Firms Out of EU Markets by July 1
The European Securities and Markets Authority confirmed April 17 that MiCA's transitional grace period closes July 1 — any firm offering crypto-asset…
FDA
Paid $5.76B: Merck's Keytruda Triplet Fails Both RCC Endpoints
Merck and Eisai's Phase 3 LITESPARK-012 study failed Tuesday.
AI
Adobe Ditches Token Pricing for AI, Charges by Outcome Now
Adobe CX Enterprise will price by ad campaigns completed, not tokens burned. The contract dispute template for outcome AI doesn't exist yet.
ai
AI
Google Wires Gemini AI Into Chrome's 3 Billion Users Overnight
Agentic AI just hit gatekeeper distribution. Chrome's Gemini rollout runs straight into DSA, DMA, and FTC questions the field hasn't answered.
ai
AI
Lloyds Picks DBS's Sameer Gupta as First Chief AI Officer, June Start
Lloyds hires DBS's Sameer Gupta to run AI from June. The UK bank AI officer arms race is on, and PRA's SS1/23 is the subtext.
ai